Paritaprevir

Paritaprevir is an orally bioavailable, direct-acting inhibitor of the hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) serine protease. It inhibits HCV replication in stable Huh7-derived replicon cell lines infected with subgenomic genotypes 1a, 1b, 2a, 3a, 4a, and 6a (EC50s = 1, 0.21, 5.3, 19, 0.09, and 0.69 nM, respectively). It also inhibits replicons from clinical isolates of genotypes 1a (EC50s = 0.43-1.87 nM) and 1b (EC50s = 0.033-0.087 nM). Formulations containing paritaprevir in combination with ombitasvir, ritonavir, and dasabuvir with and without ribavirin have been used in the treatment of chronic HCV genotype 1 infection.Formal Name: (2R,6S,12Z,13aS,14aR,16aS)-N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide. CAS Number: 1216941-48-8. Synonyms: ABT-450. Molecular Formula: C40H43N7O7S. Formula Weight: 765.9. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, DMSO:PBS (pH 7.2) (1:5): 0.17 mg/ml. lambdamax: 215, 235, 246, 322, 337 nm. SMILES: O=C1N[C@@]2(C(NS(C3CC3)(=O)=O)=O)[C@@H](C2)/C=C\CCCCC[C@H](NC(C4=CN=C(C)C=N4)=O)C(N5C[C@H](OC6=C(C=CC=C7)C7=C(C=CC=C8)C8=N6)C[C@]51[H])=O. InChi Code: InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1. InChi Key: UAUIUKWPKRJZJV-QPLHLKROSA-N.